NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $31.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the company. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a report on Monday, November 25th. Finally, Ascendiant Capital Markets lifted their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd.

NRx Pharmaceuticals Trading Up 32.8 %

NASDAQ:NRXP opened at $4.66 on Monday. The company has a market cap of $56.36 million, a P/E ratio of -2.18 and a beta of 1.08. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $7.33. The company’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.77.

Insider Activity

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average price of $1.17 per share, for a total transaction of $46,800.00. Following the acquisition, the chairman now owns 84,634 shares of the company’s stock, valued at $99,021.78. This represents a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 19.00% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned 1.33% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.